Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

Abstract

Pyrimidine nucleotide precursors including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

1 - 57 . (cancelled)  
     
     
         58 . A composition comprising: 
 a) an acyl derivative of uridine, cytidine or orotic acid; and    b) an inhibitor of uridine phosphorylase.    
     
     
         59 . A composition as in  claim 58  wherein said acyl derivative is an acyl derivative of uridine.  
     
     
         60 . A composition as in  claim 58  wherein said acyl derivative is an acyl derivative of cytidine.  
     
     
         61 . A composition as in  claim 58  wherein said acyl derivative is an acyl derivative of orotic acid.  
     
     
         62 . A composition as in  claim 59  wherein said acyl derivative of uridine is a fatty acid ester of uridine having 2-6 carbon atoms.  
     
     
         63 . A composition as in  claim 60  wherein said acyl derivative of cytidine is a fatty acid ester of cytidine having 2-6 carbon atoms.  
     
     
         64 . A composition as in  claim 59  wherein said acyl derivative of uridine is triacetyl uridine.  
     
     
         65 . A composition as in  claim 60  wherein said acyl derivative of cytidine is triacetyl cytidine.  
     
     
         66 . A composition as in  claim 58  wherein said inhibitor of uridine phosphorylase is selected from the group consisting of a 5-benzyl barbiturate derivative, a 5-benzylidene barbiturate derivative, 2,2′-anhydro-5-ethyluridine, 5-ethyl-2-deoxyuridine and an acyclouridine compound.  
     
     
         67 . A composition as in  claim 66  wherein said 5-benzyl barbiturate derivative is selected from the group consisting of 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, 5-benzyloxybenzylacetyl-2-[(1-hydroxy-2-ethoxy)methyl] barbiturate, and 5-methoxybenzylacetylacyclobarbiturate.  
     
     
         68 . A composition as in  claim 65  wherein said acyclouridine compound is a 5-benzylsubstituted acyclouridine congener selected from the group consisting of benzylacyclouridine, benzyloxybenzylacyclouridine, aminomethyl-benzylacyclouridine, aminomethylbenzyloxybenzylacyclouridine, hydroxymethyl-benzylacyclouridine, and hydroxymethyl-benzyloxybenzylacyclouridine.